• Tazi MezalekZoubidaZDepartment of Internal Medicine, Ibn Sina University Hospital, Rabat, Morocco - z.tazimezalek@gmail.com.Department of Clinical Hematology, Ibn Sina University Hospital, Rabat, Morocco - z.tazimezalek@gmail.com.Faculty of Medicine and P, Hajar Khibri, Sarra Chadli, Safae El Fari, Wafaa Ammouri, Hicham Harmouche, Mouna Maamar, and Mohamed Adnaoui.
• Department of Internal Medicine, Ibn Sina University Hospital, Rabat, Morocco - z.tazimezalek@gmail.com.
• Minerva Med. 2021 Dec 1; 112 (6): 767-778.

AbstractBehçet disease is a multi-systemic complex vasculitis with unknown etiology characterized by different clinical involvements, including mucocutaneous, ocular, vascular, articular, neurological, and gastrointestinal manifestations. Growing evidence supports that different phenotypes, characterized by clusters of co-existing involvements, can be distinguished. Namely, the vascular phenotype identifies a specific group of patients who suffer from recurrent inflammatory thrombosis and arterial involvement. Vascular disease develops in up to 40% with a definite male preponderance and is usually an early manifestation. Venous involvement is significantly more common than arterial disease, and lower extremity deep vein thrombosis is its most frequent manifestation. Arterial disease involves mostly pulmonary arteries and aorta and manifests mainly in the form of aneurysms. Glucocorticoids and immunosuppressants are the recommended first-line treatments in vasculo-Behçet. Furthermore, controlled trials are still needed to assess the role of adding anticoagulation to the treatment regimen, with an accent on new oral anticoagulants. Treatment with anti-TNF alpha agents seems promising, but the management strategies are not clear yet.

21 keywords...

hide…